Wells Fargo’s Turn Therapeutics TTRX Stock Holding History

Wells Fargo’s Portfolio TTRX Stock Details TTRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.3K	Hold	1,000	–	–	﹤0.01%	6144
2026 Q1	$3.2K	Hold	1,000	–	–	﹤0.01%	6196
2025 Q4	$3.94K	Buy	+1,000	New	+$4.17K	﹤0.01%	6145

Other funds holding TTRX

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return

Wells Fargo's TTRX Position: Q2 2026 in Review

Wells Fargo held its Turn Therapeutics (TTRX) position steady in Q2 2026 at 1,000 shares worth $7.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6144.

Wells Fargo first reported a position in TTRX in Q4 2025 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

Wells Fargo held 1,000 shares of Turn Therapeutics worth $7.3K as of Q2 2026.
Wells Fargo left its Turn Therapeutics share count unchanged in Q2 2026.
Turn Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6144 holding.
Wells Fargo first reported a position in Turn Therapeutics in Q4 2025 and has held it in 3 quarters since.
29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.